New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePancragen vs P21

Pancragen vs P21

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Pancragen
Cognitive EnhancementAnti-Aging & Longevity
P21
Summary
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
P21 is a synthetic peptide derived from CNTF (ciliary neurotrophic factor) that promotes hippocampal neurogenesis, enhances memory and spatial learning, and may reduce amyloid-beta pathology. It is used as a neurogenic and cognitive enhancer with potential anti-Alzheimer's applications.
Half-Life
Short (minutes); sustained gene-regulatory effects
Not well characterized; likely short, but neurogenic effects persist long after administration
Admin Route
SubQ, Oral
SubQ, Intranasal
Research
Typical Dose
10 mg per day
100–500 mcg
Frequency
Daily for 10–30 days
Once daily
Key Benefits
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
  • Promotes hippocampal neurogenesis
  • Enhances spatial memory and learning
  • Increases BDNF expression
  • Reduces amyloid-beta plaque formation (animal models)
  • Anti-tau pathology potential
  • Cognitive enhancement without stimulant effects
  • Potential therapeutic for Alzheimer's and cognitive aging
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
  • Generally well tolerated in animal studies
  • Limited human clinical data
  • Injection site reactions
  • Potential mild fatigue at initiation
Stacks With